Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840295 | 0.79 | ACP1 (0.41) | PARP1SCN9ANOS1HRH3AVPR1B | |
| SCHEMBL1994150 | 0.70 | DHODH (0.43) | HRH3 | |
| SCHEMBL29501461 | 0.69 | KDM4E (0.57) | KDM4E | |
| SCHEMBL840087 | 0.68 | NOS1 (0.41) | PARP1NOS1HRH3KDM4E | |
| SCHEMBL839479 | 0.68 | CYP2D6 (0.42) | PARP1SCN9AHRH3KDM4E | |
| SCHEMBL840383 | 0.67 | HDAC6 (0.39) | HRH3AVPR1B | |
| SCHEMBL840384 | 0.67 | HDAC6 (0.39) | HRH3AVPR1B | |
| SCHEMBL1996221 | 0.67 | MEN1 (0.41) | KDM4E | |
| SCHEMBL839469 | 0.67 | HRH3 (0.43) | PARP1HRH3 | |
| SCHEMBL16129946 | 0.66 | SCN9A (0.61) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143246-B2 | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives | MSD OSS B.V. (NL) | 2012-03-27 | — | — | US | disclosed |
| EP-2373639-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. Organon (NL) | 2011-10-12 | — | — | EP | disclosed |
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V.ORGANON | 2010-06-10 | — | — | US | disclosed |
| WO-2010063666-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. ORGANON (NL) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | OPRD1, CNR1, CNR2 | PARP1 2970/4885AOC3 892/4885SCN9A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.